Kpod-CV 325 Tablet
295,00 ₹
Analogs of Kpod-CV 325 Tablet
Find cheaper analogs and generic equivalents for Kpod-CV 325 Tablet.
Active Ingredient: Cefpodoxime Proxetil; Clavulanic Acid
Product Overview
About Kpod-CV 325 Tablet
Kpod-CV 325 Tablet is a medication containing the active ingredient Cefpodoxime Proxetil, classified as Antibiotic. Cefpodoxime is an oral, third-generation cephalosporin antibiotic available in various generic preparations. It is active against both Gram-positive and Gram-negative organisms with notable exceptions including Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis.
Key Benefits & Uses
- Used for: INDICATIONS AND USAGE Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains.
- Used for: Recommended dosages, durations of therapy, and applicable patient populations vary among these infections
- Use only as directed on the product label or by a healthcare professional.
Active Ingredient & Action
Cefpodoxime Proxetil, the active ingredient in Kpod-CV 325 Tablet, belongs to the Antibiotic class. INDICATIONS AND USAGE Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Inactive ingredients: not listed in source data.
Important Notes
Always read and follow the label instructions carefully before taking Kpod-CV 325 Tablet. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use Kpod-CV 325 Tablet for extended periods without medical advice.
Find in Pharmacies
Compare local prices and distance for Kpod-CV 325 Tablet.
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.